睿知中国疾病研究地图
候选清单0

即将招募鼻咽癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Becotatug Vedotin Plus Gemcitabine and a PD-1 Inhibitor in Recurrent or Metastatic Nasopharyngeal Carcinoma

ClinicalTrials.gov 上登记的一项鼻咽癌开放试验,由中山大学肿瘤防治中心牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)中山大学肿瘤防治中心Sun Yat-sen University Cancer Center广州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07902713,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 70 岁;性别:不限

    登记记录的入选字段

  2. At least one measurable lesion according to RECIST version 1.1. Previously irradiated lesions cannot be selected as target lesions unless unequivocal progression has been documented at least 3 months after the last radiotherapy.

    入选标准第 5 条

    History of another malignancy unless the patient has received potentially curative treatment and remained recurrence-free for at least 5 years. Exceptions include adequately treated basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, carcinoma in situ, and papillary thyroid carcinoma.

    排除标准第 20 条

  3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

    入选标准第 6 条

  4. Hemoglobin ≥90 g/L;

    入选标准第 8 条

    Platelet count ≥100 × 10⁹/L.

    入选标准第 10 条

    Total bilirubin <2.0 × upper limit of normal (ULN);

    入选标准第 12 条

    AST and ALT ≤2.5 × ULN in patients without liver metastases, or ≤3.0 × ULN in patients with liver metastases;

    入选标准第 13 条

    Alkaline phosphatase ≤1.5 × ULN, or ≤2.0 × ULN in patients with liver metastases;

    入选标准第 14 条

    Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or a history of grade ≥3 hypersensitivity reactions to other anti-EGFR agents or monoclonal antibodies.

    排除标准第 23 条

  5. Hepatitis B surface antigen (HBsAg) positivity with HBV DNA ≥500 IU/mL;

    排除标准第 25 条

    Hepatitis C antibody positivity with detectable HCV RNA above the lower limit of detection.

    排除标准第 26 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07902713,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Voluntary participation in the study and provision of written informed consent.
  2. Male or nonpregnant female patients aged 18-70 years.
  3. Life expectancy of at least 3 months.
  4. Histologically or cytologically confirmed recurrent or metastatic nasopharyngeal carcinoma (NPC) with treatment failure following prior platinum-based chemotherapy or PD-(L)1 inhibitor therapy. The two treatment modalities may have been administered concurrently as part of a first-line regimen or sequentially. Patients must be considered unsuitable for curative local salvage treatment, including surgery, re-irradiation, or other definitive local therapies.
  5. At least one measurable lesion according to RECIST version 1.1. Previously irradiated lesions cannot be selected as target lesions unless unequivocal progression has been documented at least 3 months after the last radiotherapy.
  6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  7. Adequate hematologic function, defined as:
  8. Hemoglobin ≥90 g/L;
  9. White blood cell count ≥4.0 × 10⁹/L;
  10. Platelet count ≥100 × 10⁹/L.
  11. Adequate hepatic function, defined as:
  12. Total bilirubin <2.0 × upper limit of normal (ULN);
  13. AST and ALT ≤2.5 × ULN in patients without liver metastases, or ≤3.0 × ULN in patients with liver metastases;
  14. Alkaline phosphatase ≤1.5 × ULN, or ≤2.0 × ULN in patients with liver metastases;
  15. Serum albumin ≥30 g/L.
  16. Adequate coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT), and activated partial thromboplastin time (APTT) ≤1.5 × ULN. Patients receiving anticoagulant therapy are eligible if their anticoagulation parameters are within the therapeutic range and are closely monitored by the investigator.
  17. Adequate renal function, defined as serum creatinine ≤1.5 × ULN, or creatinine clearance ≥50 mL/min calculated using the adjusted Cockcroft-Gault formula if serum creatinine exceeds 1.5 × ULN.
  18. Women of childbearing potential and male patients of reproductive potential must agree to use adequate contraception throughout study treatment and for 180 days after the last dose of study treatment.

排除标准:Exclusion Criteria:

  1. Histologically confirmed keratinizing squamous cell carcinoma (WHO type I).
  2. Grade ≥2 peripheral neuropathy according to CTCAE version 5.0.
  3. Anticipated requirement for surgery or any other systemic or local anticancer therapy during the study, including palliative treatment, except for palliative treatment directed at non-target lesions.
  4. Receipt of any of the following treatments before the first dose of study treatment:
  5. Systemic chemotherapy within 3 weeks;
  6. Small-molecule targeted therapy within 2 weeks or 5 half-lives, whichever is longer;
  7. Anticancer biological therapy, macromolecular targeted therapy, or immunotherapy within 4 weeks;
  8. Major surgery within 4 weeks, except for minor surgery performed within 2 weeks with complete recovery;
  9. Radiotherapy within 14 days, or radiotherapy to the central nervous system within 28 days.
  10. Known active central nervous system (CNS) metastases or carcinomatous meningitis. Patients with previously treated brain metastases may be eligible if clinically stable, without progressive or new neurological deficits, seizures, evidence of increased intracranial pressure, vomiting, or headache, and without evidence of lesion enlargement on MRI during the preceding 4 weeks or a requirement for corticosteroids during the 14 days before the first dose of study treatment.
  11. Residual toxicities from previous anticancer treatment, including immunotherapy, targeted therapy, chemotherapy, or radiotherapy, or clinically significant laboratory abnormalities greater than grade 1 according to CTCAE version 5.0, except for alopecia, fatigue, and grade 2 hypothyroidism.
  12. Uncontrolled or poorly controlled cardiovascular disease, including any of the following:
  13. Grade ≥2 congestive heart failure within 6 months before enrollment;
  14. Myocardial infarction or unstable angina;
  15. History of ventricular tachycardia or torsades de pointes;
  16. Clinically significant arrhythmias requiring treatment;
  17. QTcF >450 ms in males or >470 ms in females;
  18. Complete left bundle branch block or third-degree atrioventricular block.
  19. Pulmonary embolism or deep vein thrombosis within 3 months before the first dose of study treatment, except for thrombosis associated with an implanted venous port or peripherally inserted central catheter (PICC).
  20. History of another malignancy unless the patient has received potentially curative treatment and remained recurrence-free for at least 5 years. Exceptions include adequately treated basal cell carcinoma of the skin, superficial bladder cancer, cutaneous squamous cell carcinoma, carcinoma in situ, and papillary thyroid carcinoma.
  21. Any severe or uncontrolled systemic disease, including poorly controlled hypertension (systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg) or poorly controlled diabetes mellitus (HbA1c >8%).
  22. Active bleeding, history of a bleeding or coagulation disorder, or current treatment with coumarin anticoagulants.
  23. Known hypersensitivity to any component or excipient of becotatug vedotin, including citric acid monohydrate, sodium citrate dihydrate, trehalose dihydrate, sodium chloride, and polysorbate 80; or a history of grade ≥3 hypersensitivity reactions to other anti-EGFR agents or monoclonal antibodies.
  24. Active hepatitis B or hepatitis C infection, defined as:
  25. Hepatitis B surface antigen (HBsAg) positivity with HBV DNA ≥500 IU/mL;
  26. Hepatitis C antibody positivity with detectable HCV RNA above the lower limit of detection.
  27. Severe uncontrolled infection, known HIV infection, or acquired immunodeficiency syndrome (AIDS); active autoimmune disease, except for type 1 diabetes mellitus, hypothyroidism controlled with replacement therapy, or skin disorders not requiring systemic treatment (such as vitiligo, psoriasis, or alopecia); or a history of allogeneic tissue or organ transplantation, stem cell transplantation, or bone marrow transplantation.
  28. Active bacterial, viral, fungal, rickettsial, or parasitic infection requiring systemic antimicrobial treatment, unless adequately treated and resolved before the first dose of study treatment.
  29. Receipt of a live-virus vaccine within 30 days before the first dose of study treatment.
  30. History of or concurrent interstitial pneumonitis, severe chronic obstructive pulmonary disease with respiratory failure, severe pulmonary dysfunction, or symptomatic bronchospasm.
  31. Receipt of immunologically based treatment for any reason, including chronic systemic corticosteroid therapy equivalent to >10 mg/day of prednisone within 7 days before the first dose of study treatment or during study participation. Inhaled or topical corticosteroids, systemic corticosteroids equivalent to ≤10 mg/day of prednisone, and short-term corticosteroid use at higher doses for specific indications (such as premedication before contrast administration) are permitted.
  32. Uncontrolled pleural, abdominal, pelvic, or pericardial effusion requiring drainage at least once per month.
  33. Positive pregnancy test, current breastfeeding, or unwillingness to use adequate contraception during study treatment and for 180 days after the last dose of study treatment.
  34. Any other disease, clinically significant laboratory abnormality, serious medical or psychiatric condition, or substance abuse (including alcohol abuse) that, in the investigator's judgment, may compromise patient safety, study integrity, study participation, or interpretation of study results.

引自 ClinicalTrials.gov, NCT07902713, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07902713,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07902713